Extracellular Vesicles as Vehicles for the Delivery ... - ACS Publications

Subscriber access provided by UNIV OF LOUISIANA

Perspective

Extracellular vesicles as vehicles for the delivery of food bioactives Agnes Reiner, and Veronika Somoza J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.8b06369 • Publication Date (Web): 28 Jan 2019 Downloaded from http://pubs.acs.org on January 28, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 22

Journal of Agricultural and Food Chemistry

1

Extracellular Vesicles as Vehicles for the Delivery of Food Bioactives

2

Agnes T. Reiner 1, Veronika Somoza 1†

3 4

1

5

†

Department of Physiological Chemistry, Faculty of Chemistry, University of Vienna, Althanstraße 14 UZA II, 1090 Vienna, Austria Corresponding author: [email protected], telephone: +4314277-70611

6 7

Keywords: Extracellular vesicles, drug delivery, bioactives, food additives

8

1 ACS Paragon Plus Environment


9

Page 2 of 22

Abstract:

10

The nutritional value of foods can be improved by the addition of bioactive compounds.

11

However, most of these favorable food additives demonstrate a low bioavailability because of

12

their limited stability, solubility, and structural transformations upon digestion and

13

absorption. One strategy to combat these limitations is to integrate bioactives into

14

nanoparticles, although the mostly used artificial materials may result in immune system

15

activation and fast clearing times. Therefore, novel, more biocompatible delivery systems are

16

required. Extracellular vesicles are communication tools designed by evolution to transfer

17

information between cells, organs, and whole organisms. Hence, these vesicles offer an

18

enormous potential for targeted bioactive compound delivery.

19


Page 3 of 22


20

Introduction

21

Bioactive compounds, like polyphenols, vitamins or polyunsaturated fatty acids, are often

22

added to foods to increase their nutritional value. However, the effect of such bioactives can

23

be impaired by their poor bioavailability due to structural transformations upon digestion and

24

absorption, their limited water solubility, and metabolic transformations. For some of the

25

bioactives, side effects, e.g., as interactions with drugs, are reported. For instance,

26

polyphenolic compounds from bilberry extracts can inhibit the cytostatic effect of the

27

anticancer drug erlotinib 1. Although the emergence of nanotechnology and the use of

28

nanoparticles has markedly improved the bioavailability of food bioactives, nanoparticles may

29

also demonstrate non-desired effects as they may cause immune reactions and sometimes

30

even cytotoxicity. Cellular clearance of nanoparticles is also of concern since nanoparticles

31

have been shown to be taken up by, e.g., intestinal cells

32

mechanism has been identified yet. Within the last decades, a new class of cellular secretion

33

products, namely extracellular vesicles (EVs), has emerged that demonstrates an enormous

34

potential to achieve highly efficient delivery of bioactive compounds while overcoming many

35

of the mentioned issues.

36

Scientific Relevance of EVs

37

The history of EVs started in the early 1980’s with the discovery of exosomes, one class of EVs.

38

Two independent groups 4-5 identified lipid vesicles in the size of about 100 nm in diameter

39

that were formed and secreted by a novel pathway described in more detail below. At this

40

early stage, researchers believed that exosomes were only built as a cellular waste disposal

41

system for removal of unneeded proteins. It took about another 15 years until exosomes

42

gained more attention, when Raposo et al. 6 discovered that such small lipid vesicles were also

2-3

but no cellular excretion



43

secreted by B lymphocytes and were able to activate T cells via antigen presentation and MHC

44

class II signaling, thereby triggering an immune response. Based on these findings, a new field

45

of research developed that is still on the rise with publication records exponentially increasing

46

over the last ten years. Nowadays, we know that EVs are important players in intercellular

47

communication and transfer information as proteins, nucleic acids and lipids from one cell to

48

another. EVs are secreted by all types of cells and are found in biofluids like blood, saliva,

49

urine, cerebrospinal fluid, breast milk and others 7. EVs are also not just limited to humans and

50

other mammals, they are produced by cells across all kingdoms, as they have been identified

51

and isolated from bacteria, protozoa, or plants 7. Most interestingly, EVs were shown to

52

transfer information, in particular small RNAs, across kingdoms, for instance from plants to

53

fungi to inactivate virulence genes 8. A transfer of plant micro RNAs contained in EVs to

54

mammals through food uptake has also been suggested 9. Even though such findings are

55

especially interesting for the field of agriculture and food, so far, EVs are topic of only very few

56

studies in this area. The majority of records on EVs found in Web of Science are categorized in

57

the fields of cell biology, biochemistry, oncology, and several other fields associated to

58

biomedicine, as illustrated in Figure 1, which shows the top 15 categories that comprise most

59

of the records on EVs of the year 2017. Web of Science records on EVs were also found in the

60

categories “Food Science Technology”, “Nutrition Dietetics”, “Plant Sciences”, “Agriculture

61

Dairy Animal Science”, “Agriculture Multidisciplinary”, and “Agronomy”, which are associated

62

to the field of agriculture and food, but they sum up to only 55 of a total number of 3,482

63

records on EVs, which corresponds to 1.58 %.

64

Besides the fact that EVs are a young research field with many open questions that are studied

65

by basic science, applications of EVs are already on the rise. For instance, EVs evolved as a new

66

class or source of biomarkers, since they are found in many biological fluids and therefore can 4 ACS Paragon Plus Environment

Page 4 of 22

Page 5 of 22


67

be used as non-invasive biomarkers. For this purpose, the different constituents of EVs,

68

namely proteins, small RNAs, and lipids, or simply the concentration of EVs demonstrate a

69

potential as diagnostic or prognostic biomarkers for a wide range of diseases. Furthermore,

70

based on the physiological functions of EVs, their application as active agents or therapeutics

71

in the fields of tissue regeneration, immune modulation, cancer therapy and others are

72

studied. Another application of EVs is their use for targeted delivery of compounds to cells.

73

Since EVs are built naturally by cells with the purpose to deliver information to other cells,

74

they are an optimal system for compound delivery. Furthermore, EVs can be harvested from

75

sources like milk, which is safe for human ingestion and readily available in large quantities.

76

So far, EVs have been intensely studied for drug delivery over the last years, as illustrated by

77

the rising numbers of publications in Figure 1A. Most of these studies explore the potential of

78

EVs in medical applications, and their findings could be translated to the field of bioactives’

79

delivery via foods. This perspectives paper summarizes the key characteristics of EVs and

80

compares their potential with artificially produced delivery systems like liposomes.

81

Types of EVs, Biogenesis and Characteristics

82

According to the International Society of Extracellular Vesicles (ISEV), EVs are categorized into

83

three groups depending on their biogenesis: exosomes, microvesicles, and apoptotic bodies.

84

As illustrated in Figure 2A and reviewed by van Niel et al. 10, exosomes are built through the

85

inward budding of the late endosomal membrane, leading to the formation of multivesicular

86

bodies, which later fuse with the plasma membrane and secrete the contained exosomes to

87

the extracellular space. Microvesicles, on the other hand, form through direct budding from

88

the plasma membrane. The third class of EVs are apoptotic bodies, which are generated during

89

the process of controlled cell death. These vesicles are just mentioned for completeness, but 5 ACS Paragon Plus Environment


Page 6 of 22

90

they have no value for applications in drug delivery and are therefore not discussed further.

91

In this article, the term of EVs only relates to exosomes and microvesicles.

92

The size of EVs ranges from a few 10 nm to about 1000 nm in diameter, with exosomes tending

93

to be smaller than microvesicles 11. Generally, all EVs are surrounded by a lipid bilayer, which,

94

due to their biogenensis, has the same orientation as the cellular plasma membrane. Figure

95

2B shows cryo-electron microscopy images of EVs, for illustration of the size and shape of EVs.

96

Labelling with gold nanoparticles was used to better characterize the lipid bilayer of the

97

imaged vesicles 12. EVs contain soluble and transmembrane proteins, as well as different types

98

of nucleic acids, including small RNA, micro RNA, messenger RNA, and DNA. Their composition

99

is specific for their secreting cell and the loading is performed by distinct and controlled

100

pathways within the cells 10. However, the exact pathways and mechanisms responsible for

101

the formation and specific loading of EVs is not yet known. The composition of EVs results in

102

distinct functions of vesicles and the ability to target specific cells. The diverse physiological

103

functions of EVs were extensively reviewed by Yanez-Mo et al. 7. EVs are able to exert their

104

function via receptor signaling from the outside, or release of their cargo into the cytoplasm

105

via endocytosis or fusion with the target cell membrane. Especially interesting is the finding

106

that cargo molecules of EVs can also be transported into the cell nucleus of the recipient cells

107

and it has been suggested that they are transported by a novel mechanism independent of

108

the known nuclear translocation sequence pathway 13.

109

As mentioned in the introduction, EVs are not only found and produced in the human body.

110

They have also been identified in all kinds of animals and plants. For the field of agriculture

111

and food, the presence of EVs in crop plants, life stock, and natural food products is of special

112

interest. For example, EVs in milk of diverse mammalian species are studied already in great 6 ACS Paragon Plus Environment

Page 7 of 22


113

detail, while the identification of EVs in plants and fruits, like carrots, ginger, nuts, seeds,

114

grapefruits, grapes, watermelons, and others, are still in its beginnings. More details on the

115

identification of EVs in food and their potential functions can be found in the review of Perez-

116

Bermudez et al. 14.

117

Concerning the methods used for isolation, characterization, and functional analysis there are

118

plenty of different approaches currently used in EV research, but no optimal or standard

119

protocols have been identified so far. Nevertheless, a primary aim of the International Society

120

of Extracellular Vesicles is to support and pursue standardization within the field. More

121

information on different methods for EV research can be found in one of ISEV’s position

122

papers

123

researchers in planning and setting up their experiments 16.

124

EVs as delivery tool for bioactives

125

EVs are purposed to transfer cargo molecules between cells in close proximity but also to

126

distant sites. They have been designed and built by evolution to become a perfect tool for

127

cellular communication. Consequently, EVs offer significant advantages for the use as delivery

128

tool compared to artificial nanoparticles. In the following paragraphs, the characteristics of

129

EVs as drug delivery system are compared to those of artificial nanoparticles. Due to the great

130

variety of nanoparticles and their properties, only liposomes are used for comparison, because

131

these are the most similar representatives of nanoparticles to EVs. The key characteristics of

132

biological nanoparticles (EVs) and artificial nanoparticles (liposomes) for the use as drug

133

delivery system are summarized in Table 1 and discussed point by point in the following

134

paragraphs and sections.

15

and the just recently published requirements for studies of EVs that should assist



135

First of all, EVs have the inherent function of protecting molecules from the extracellular

136

environment and delivering them to their target cells or tissues, while liposomes need to be

137

engineered and artificially synthesized to be useful for applications. Due to their composition

138

of a lipophilic membrane layer and a hydrophilic core, both, EVs and liposomes, are able to

139

carry lipophilic and hydrophilic compounds, allowing a wide range of applications. Moreover,

140

the small biological vesicles stand out due to their extremely high stability in harsh

141

environments. Besides the finding that the lipid bilayer protects their cargo from enzymatic

142

degradation by nucleases or proteinases, EVs can resist low pH, high sheer stress, prolonged

143

times at body temperature, all found in human digestion. This has already been proven for

144

milk- 17 and grapefruit- 18 derived EVs by exposing the vesicles to a mimicked digestive system

145

in vitro, including digestive juices, enzymatic activity and physical conditions. Since bioactives

146

are added to foods that are taken up orally, the resistance of EVs to digestion is extremely

147

important for protection of the bioactive compound. Moreover, the ability of EVs to protect

148

their cargo from the environment could also be used the other way around and prevent

149

interactions of the bioactive with pharmaceuticals present in the human body. However, this

150

potential effect was not studied yet. Of course, liposomes protect their cargo as well, since

151

this is one of their major functions, but their stability is greatly dependent on the materials

152

that are used.

153

The next hurdle for bioactive compound delivery systems is the uptake by cells, typically by

154

intestinal cells. Several studies have shown that natural EVs, isolated from plants or milk and

155

artificially loaded with drugs, are readily taken up by intestinal cells in vitro and in vivo,

156

respectively

157

agriculture and food, since food-derived EVs could be used as delivery vehicle, which is

158

generally safe and non-toxic to humans based on the fact that humans have been exposed to 8

19-21.

These findings are of particular interest for applications in the field of

ACS Paragon Plus Environment

Page 8 of 22

Page 9 of 22


159

these plant- or milk-derived EVs over centuries without experiencing negative effects. Quite

160

the contrary, food-derived EVs might even have beneficial physiological functions in the

161

human body, as suggested by Mu et al.

162

grapefruit, ginger, or carrots had differing anti-inflammatory, antioxidant or pro-proliferative

163

effects on the intestinal macrophages. Such effects could further enhance the activity of

164

bioactive compounds integrated into the EVs. However, the bioactivity of EVs by themselves

165

could also limit their use as drug delivery system, because many physiological functions are

166

yet unknown. In this regard, liposomes are very well established delivery systems, as they have

167

been studied already for several decades and their composition can be optimized for efficient

168

stability and cellular uptake and low or no side effects.

169

The small size in the nanoscale enables both liposomes and EVs to cross barriers within the

170

human body easier compared to larger particles. This advantage of nanoparticles is critical for

171

the efficient delivery of the cargo molecules to their target cells and tissues. However, certain

172

highly regulated barriers, like the blood-brain barrier, still pose a big hurdle for artificially

173

produced liposomes. EVs could solve these issues, because they are able to cross the blood-

174

brain barrier as shown in studies by Alvarez-Erviti et al.

175

exosomes to the mouse brain after intravenous injections. Hence, bioactive compounds that

176

are supposed to trigger reactions in the central nervous system could be transferred from the

177

digestive tract via the blood system into the brain by EVs.

178

The finding that EVs present in tissues or circulating in the blood system are not recognized

179

and cleared by the immune system due to their natural composition, explains the long

180

circulation times and high bioavailability of EVs. Liposomes on the other hand need to be

181

modified, for example by polyethylene glycol coatings, to achieve better immune-tolerance,

21

who showed that EVs derived from grapes,

22

who administered siRNA via



Page 10 of 22

182

but such coatings may negatively influence the interaction with target cells. In addition to this

183

low immunogenic profile, drug delivery systems also need to be safe and non-toxic to the

184

human body. For EVs, this can be very dependent on the cell of origin and the inherent

185

biological functions of the vesicles. For instance, EVs derived from cancer cells bear the risk of

186

transferring pro-cancerous activities, therefore they might not be safe to use for compound

187

delivery. Food-derived EVs, on the other hand, could be a much safer approach. Somiya et al.

188

23,

189

being administered intravenously.

190

Besides the efficacy of delivery systems in their function, their efficient and economic

191

production is also of importance for their successful application. In this regard, the source of

192

the material has to be chosen carefully. The material for encapsulation of the compound has

193

to be available in large enough quantities and at affordable prices, which are both

194

requirements for scale-up and commercial distribution of the encapsulated compound as food

195

additive. For EVs, both can be achieved through the use of foods as source. Bovine milk has

196

already been studied as a source for EVs intensively and showed promising results for drug

197

and bioactive compound delivery

198

great potential because of their availability and safety. Additionally, the material has to be

199

compatible with the food matrix it is supposed to be added to, which again favors the use of

200

food-derived EVs.

201

When it comes to loading and encapsulation of the bioactive compound into EVs, several

202

different approaches can be followed. Isolated EVs, that contain no bioactive material, can

203

simply be mixed together with the compound of interest and the loading is performed by

204

diffusion, electroporation or chemical transfection. This approach is basically the same as

for example, showed that EVs isolated from bovine milk are well tolerated by mice after

24-25.

Furthermore, EVs isolated from edible plants show


Page 11 of 22


205

performed for liposomes. As example, Aqil et al.

206

anthocyanidines into milk-derived EVs this way and studied their anti-tumor activity in vitro

207

and in vivo. In more detail, the study showed that the survival of drug-resistant ovarian cancer

208

OVCA433 cells decreased when incubated with the encapsulated compounds compared to the

209

free anthocyanidines. Similarly, when administering the compounds orally to mice in a

210

xenograft approach using ovarian cancer A2780 cells, the resulting tumor volume was

211

significantly lower in mice that had received the anthocyanidines encapsulated into EVs after

212

17 days of treatment. Another approach is to engineer the cellular source of EVs in order to

213

let the cell pack the compound of interest into the EVs already before secretion. This approach

214

of course requires a deep understanding of gene editing and knowledge on the pathways

215

involved in EV biogenesis, which can be limiting. Nevertheless, the technique also allows to

216

include molecules for targeting of EVs to certain organs, tissues or cells for drug release. This

217

cellular transfection-based approach to load EVs has already been applied for delivery of

218

proteins 27, small RNA molecules 28 or for triggering signaling cascades like immune responses

219

in the recipient cells 29. A third way to load EVs is the possibility to fuse biological vesicles with

220

artificial liposomes. With this strategy, the best of both fields could be combined by using the

221

biological membrane of EVs to achieve higher biocompatibility and fuse them with liposomes

222

containing the targeting or tagging molecules and the active compound. Just very recently, a

223

novel technique for EV-liposome fusion was demonstrated by Piffoux et al.

224

polyethylene glycol to merge biological EVs derived from human umbilical vein endothelial

225

cells or mesenchymal stem cells with artificially produced liposomes loaded with different

226

cargoes. Furthermore, EVs that naturally contain bioactive compounds could be used, for

227

instance from plants that produce polyphenols that are secreted via EVs by nature. In this way,

26

successfully incorporated berry

30,

who used



Page 12 of 22

228

EVs could also be considered as a therapeutic agent themselves rather than a delivery system,

229

since their inherent biological function is used without any alterations 19.

230

Limitations of EVs as delivery tool

231

Besides the promising potential of EVs as tool for bioactive compound delivery, there are also

232

limitations. Since the field of research on EVs is rather new, many uncertainties need to be

233

addressed in order to use these biological vesicles. First of all, studies are difficult to compare

234

and results to interpret, because of the lack of standardized methods for isolation, qualitative

235

and quantitative analysis or engineering of EVs. Hence, the optimal or best-suited methods

236

for each application have to be developed, which is time and resource consuming. In addition,

237

the differentiation and separation between different types and subpopulations of EVs is still a

238

challenge for the field. For example, it is already known that a cell secretes a wide variety of

239

vesicle subpopulations that could have different functions. Furthermore, the composition and

240

function of the secreted EVs are highly dependent on the conditions of the cell of origin.

241

Consequently, procedures for the production of EVs applied in compound delivery need to be

242

further developed.

243

Since EVs are produced by cells, their size is determined by their biogenesis, thus limiting their

244

loading capacity. Theoretically, artificially produced liposomes can be synthesized in any size

245

and with unlimited loading capacity. However, in most applications, the small size in the

246

nanoscale is desirable, because such delivery vehicles have superior abilities in crossing

247

barriers and penetrating into tissues compared to bigger particles.

248

As their denomination already states, bioactive compounds are actively interacting with

249

biological systems. This not only includes cells, but also EVs. Hence, bioactives encapsulated

250

in EVs could also interact with the delivery system and consequently change the vesicle’s 12 ACS Paragon Plus Environment

Page 13 of 22


251

behavior or vice versa be inactivated or metabolized by molecules present in EVs.

252

Furthermore, such changes could influence the interaction of the encapsulated compound

253

with the gastro-intestinal tract, thus influencing cellular uptake. This of course is highly

254

dependent on the particular type of EVs and compounds used in the particular application. Up

255

to now, the knowledge on interactions of different EVs and bioactive compounds with each

256

other and with the gastro-intestinal tract are very scarce, which limits the application of EVs

257

as vehicle for delivery of bioactive compounds.

258

Furthermore, there are still unsolved issues with regulatory affairs of the application of EVs in

259

therapy, because they are new and there is no clear definition what class of drugs they belong

260

to and no consensus has yet been reached on how they should be classified for approval.

261

Moreover, safety is an issue, because of the diverse unknown functions, lack of standard

262

procedures, and potentially harmful sources of EVs, like cancer-derived or immortalized cell

263

lines, as mentioned above. However, if alternative, innocuous sources like milk or edible plants

264

are used, safety concerns and approval by regulatory agencies should not be a problem.

265

Besides, over time these issues will be resolved, as seen in any newly evolving field.

266

Another concern regarding the safety of EVs is their potential to interact not only with

267

physiological processes of the human body, but also with pharmaceuticals or drugs. Such side

268

effects have not been addressed so far and need to be considered before a broad application

269

of EVs as food additives can be achieved.

270

Outlook

271

Albeit these limitations, EVs open up new possibilities for targeted delivery of bioactive food

272

compounds. Since there is urgent need for the standardization of methods of both isolation

273

and analysis, their current use might not be beneficial in all applications and already 13 ACS Paragon Plus Environment


Page 14 of 22

274

established approaches, like the use of liposomes, could still be more effective and efficient

275

for now. Nevertheless, with the growing research in the field of EVs their limitations will be

276

addressed and, if solved, EVs could be applied as delivery system for food additives and drugs,

277

thereby finding their way into the market.

278

Besides their application as delivery tool for bioactives, EVs could also serve as active

279

compounds and food additives themselves, due to their diverse physiological functions.

280

Extending findings from human medical research, EVs could also be used in therapeutic

281

approaches to fight animal and crop pathologies, as well as serve as biomarkers for health

282

monitoring and quality assurance of livestock, since they are present in biological fluids of

283

animals, like blood, saliva, or milk. Since both applications, therapeutics and biomarkers, are

284

topics of medical studies, the research field of agriculture and food could make use of the

285

available information and translate findings on EVs from biomedicine to veterinary medicine

286

and animal health, food technology and development, and agricultural and plant science.


Page 15 of 22


288

References

289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336

1. 2. 3. 4. 5. 6. 7.

8. 9.

10. 11. 12.

13. 14. 15.

Aichinger, G.; Pahlke, G.; Nagel, L. J.; Berger, W.; Marko, D., Bilberry extract, its major polyphenolic compounds, and the soy isoflavone genistein antagonize the cytostatic drug erlotinib in human epithelial cells. Food Funct 2016, 7 (8), 3628-36. Gehrke, H.; Pelka, J.; Hartinger, C. G.; Blank, H.; Bleimund, F.; Schneider, R.; Gerthsen, D.; Brase, S.; Crone, M.; Turk, M.; Marko, D., Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations. Arch Toxicol 2011, 85 (7), 799-812. Blank, H.; Schneider, R.; Gerthsen, D.; Gehrke, H.; Jarolim, K.; Marko, D., Application of lowenergy scanning transmission electron microscopy for the study of Pt-nanoparticle uptake in human colon carcinoma cells. Nanotoxicology 2014, 8 (4), 433-46. Harding, C.; Heuser, J.; Stahl, P., Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983, 97 (2), 329-39. Pan, B. T.; Johnstone, R. M., Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33 (3), 967-78. Raposo, G.; Nijman, H. W.; Stoorvogel, W.; Liejendekker, R.; Harding, C. V.; Melief, C. J.; Geuze, H. J., B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183 (3), 1161-72. Yanez-Mo, M.; Siljander, P. R.; Andreu, Z.; Zavec, A. B.; Borras, F. E.; Buzas, E. I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; Colas, E.; Cordeiro-da Silva, A.; Fais, S.; Falcon-Perez, J. M.; Ghobrial, I. M.; Giebel, B.; Gimona, M.; Graner, M.; Gursel, I.; Gursel, M.; Heegaard, N. H.; Hendrix, A.; Kierulf, P.; Kokubun, K.; Kosanovic, M.; Kralj-Iglic, V.; Kramer-Albers, E. M.; Laitinen, S.; Lasser, C.; Lener, T.; Ligeti, E.; Line, A.; Lipps, G.; Llorente, A.; Lotvall, J.; Mancek-Keber, M.; Marcilla, A.; Mittelbrunn, M.; Nazarenko, I.; Nolte-'t Hoen, E. N.; Nyman, T. A.; O'Driscoll, L.; Olivan, M.; Oliveira, C.; Pallinger, E.; Del Portillo, H. A.; Reventos, J.; Rigau, M.; Rohde, E.; Sammar, M.; Sanchez-Madrid, F.; Santarem, N.; Schallmoser, K.; Ostenfeld, M. S.; Stoorvogel, W.; Stukelj, R.; Van der Grein, S. G.; Vasconcelos, M. H.; Wauben, M. H.; De Wever, O., Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015, 4, 27066. Cai, Q.; Qiao, L.; Wang, M.; He, B.; Lin, F. M.; Palmquist, J.; Huang, S. D.; Jin, H., Plants send small RNAs in extracellular vesicles to fungal pathogen to silence virulence genes. Science 2018, 360 (6393), 1126-9. Zhang, L.; Hou, D.; Chen, X.; Li, D.; Zhu, L.; Zhang, Y.; Li, J.; Bian, Z.; Liang, X.; Cai, X.; Yin, Y.; Wang, C.; Zhang, T.; Zhu, D.; Zhang, D.; Xu, J.; Chen, Q.; Ba, Y.; Liu, J.; Wang, Q.; Chen, J.; Wang, J.; Wang, M.; Zhang, Q.; Zhang, J.; Zen, K.; Zhang, C. Y., Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res 2012, 22 (1), 107-26. van Niel, G.; D'Angelo, G.; Raposo, G., Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 2018, 19 (4), 213-28. Colombo, M.; Raposo, G.; Thery, C., Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014, 30, 255-89. Reiner, A. T.; Tan, S.; Agreiter, C.; Auer, K.; Bachmayr-Heyda, A.; Aust, S.; Pecha, N.; Mandorfer, M.; Pils, D.; Brisson, A. R.; Zeillinger, R.; Lim, S. K., EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. Dis Markers 2017, 2017 (9653194), 9. Read, J.; Ingram, A.; Al Saleh, H. A.; Platko, K.; Gabriel, K.; Kapoor, A.; Pinthus, J.; Majeed, F.; Qureshi, T.; Al-Nedawi, K., Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. Eur J Cancer 2017, 70, 62-74. Perez-Bermudez, P.; Blesa, J.; Soriano, J. M.; Marcilla, A., Extracellular vesicles in food: Experimental evidence of their secretion in grape fruits. Eur J Pharm Sci 2017, 98, 40-50. Witwer, K. W.; Buzas, E. I.; Bemis, L. T.; Bora, A.; Lasser, C.; Lotvall, J.; Nolte-'t Hoen, E. N.; Piper, M. G.; Sivaraman, S.; Skog, J.; Thery, C.; Wauben, M. H.; Hochberg, F., Standardization of sample



337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388

16.

Page 16 of 22

collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles 2013, 2, 20360. Thery, C.; Witwer, K. W.; Aikawa, E.; Alcaraz, M. J.; Anderson, J. D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G. K.; Ayre, D. C.; Bach, J. M.; Bachurski, D.; Baharvand, H.; Balaj, L.; Baldacchino, S.; Bauer, N. N.; Baxter, A. A.; Bebawy, M.; Beckham, C.; Bedina Zavec, A.; Benmoussa, A.; Berardi, A. C.; Bergese, P.; Bielska, E.; Blenkiron, C.; BobisWozowicz, S.; Boilard, E.; Boireau, W.; Bongiovanni, A.; Borras, F. E.; Bosch, S.; Boulanger, C. M.; Breakefield, X.; Breglio, A. M.; Brennan, M. A.; Brigstock, D. R.; Brisson, A.; Broekman, M. L.; Bromberg, J. F.; Bryl-Gorecka, P.; Buch, S.; Buck, A. H.; Burger, D.; Busatto, S.; Buschmann, D.; Bussolati, B.; Buzas, E. I.; Byrd, J. B.; Camussi, G.; Carter, D. R.; Caruso, S.; Chamley, L. W.; Chang, Y. T.; Chen, C.; Chen, S.; Cheng, L.; Chin, A. R.; Clayton, A.; Clerici, S. P.; Cocks, A.; Cocucci, E.; Coffey, R. J.; Cordeiro-da-Silva, A.; Couch, Y.; Coumans, F. A.; Coyle, B.; Crescitelli, R.; Criado, M. F.; D'Souza-Schorey, C.; Das, S.; Datta Chaudhuri, A.; de Candia, P.; De Santana, E. F.; De Wever, O.; Del Portillo, H. A.; Demaret, T.; Deville, S.; Devitt, A.; Dhondt, B.; Di Vizio, D.; Dieterich, L. C.; Dolo, V.; Dominguez Rubio, A. P.; Dominici, M.; Dourado, M. R.; Driedonks, T. A.; Duarte, F. V.; Duncan, H. M.; Eichenberger, R. M.; Ekstrom, K.; El Andaloussi, S.; Elie-Caille, C.; Erdbrugger, U.; Falcon-Perez, J. M.; Fatima, F.; Fish, J. E.; Flores-Bellver, M.; Forsonits, A.; Frelet-Barrand, A.; Fricke, F.; Fuhrmann, G.; Gabrielsson, S.; Gamez-Valero, A.; Gardiner, C.; Gartner, K.; Gaudin, R.; Gho, Y. S.; Giebel, B.; Gilbert, C.; Gimona, M.; Giusti, I.; Goberdhan, D. C.; Gorgens, A.; Gorski, S. M.; Greening, D. W.; Gross, J. C.; Gualerzi, A.; Gupta, G. N.; Gustafson, D.; Handberg, A.; Haraszti, R. A.; Harrison, P.; Hegyesi, H.; Hendrix, A.; Hill, A. F.; Hochberg, F. H.; Hoffmann, K. F.; Holder, B.; Holthofer, H.; Hosseinkhani, B.; Hu, G.; Huang, Y.; Huber, V.; Hunt, S.; Ibrahim, A. G.; Ikezu, T.; Inal, J. M.; Isin, M.; Ivanova, A.; Jackson, H. K.; Jacobsen, S.; Jay, S. M.; Jayachandran, M.; Jenster, G.; Jiang, L.; Johnson, S. M.; Jones, J. C.; Jong, A.; Jovanovic-Talisman, T.; Jung, S.; Kalluri, R.; Kano, S. I.; Kaur, S.; Kawamura, Y.; Keller, E. T.; Khamari, D.; Khomyakova, E.; Khvorova, A.; Kierulf, P.; Kim, K. P.; Kislinger, T.; Klingeborn, M.; Klinke, D. J., 2nd; Kornek, M.; Kosanovic, M. M.; Kovacs, A. F.; Kramer-Albers, E. M.; Krasemann, S.; Krause, M.; Kurochkin, I. V.; Kusuma, G. D.; Kuypers, S.; Laitinen, S.; Langevin, S. M.; Languino, L. R.; Lannigan, J.; Lasser, C.; Laurent, L. C.; Lavieu, G.; Lazaro-Ibanez, E.; Le Lay, S.; Lee, M. S.; Lee, Y. X. F.; Lemos, D. S.; Lenassi, M.; Leszczynska, A.; Li, I. T.; Liao, K.; Libregts, S. F.; Ligeti, E.; Lim, R.; Lim, S. K.; Line, A.; Linnemannstons, K.; Llorente, A.; Lombard, C. A.; Lorenowicz, M. J.; Lorincz, A. M.; Lotvall, J.; Lovett, J.; Lowry, M. C.; Loyer, X.; Lu, Q.; Lukomska, B.; Lunavat, T. R.; Maas, S. L.; Malhi, H.; Marcilla, A.; Mariani, J.; Mariscal, J.; Martens-Uzunova, E. S.; Martin-Jaular, L.; Martinez, M. C.; Martins, V. R.; Mathieu, M.; Mathivanan, S.; Maugeri, M.; McGinnis, L. K.; McVey, M. J.; Meckes, D. G., Jr.; Meehan, K. L.; Mertens, I.; Minciacchi, V. R.; Moller, A.; Moller Jorgensen, M.; MoralesKastresana, A.; Morhayim, J.; Mullier, F.; Muraca, M.; Musante, L.; Mussack, V.; Muth, D. C.; Myburgh, K. H.; Najrana, T.; Nawaz, M.; Nazarenko, I.; Nejsum, P.; Neri, C.; Neri, T.; Nieuwland, R.; Nimrichter, L.; Nolan, J. P.; Nolte-'t Hoen, E. N.; Noren Hooten, N.; O'Driscoll, L.; O'Grady, T.; O'Loghlen, A.; Ochiya, T.; Olivier, M.; Ortiz, A.; Ortiz, L. A.; Osteikoetxea, X.; Ostergaard, O.; Ostrowski, M.; Park, J.; Pegtel, D. M.; Peinado, H.; Perut, F.; Pfaffl, M. W.; Phinney, D. G.; Pieters, B. C.; Pink, R. C.; Pisetsky, D. S.; Pogge von Strandmann, E.; Polakovicova, I.; Poon, I. K.; Powell, B. H.; Prada, I.; Pulliam, L.; Quesenberry, P.; Radeghieri, A.; Raffai, R. L.; Raimondo, S.; Rak, J.; Ramirez, M. I.; Raposo, G.; Rayyan, M. S.; Regev-Rudzki, N.; Ricklefs, F. L.; Robbins, P. D.; Roberts, D. D.; Rodrigues, S. C.; Rohde, E.; Rome, S.; Rouschop, K. M.; Rughetti, A.; Russell, A. E.; Saa, P.; Sahoo, S.; Salas-Huenuleo, E.; Sanchez, C.; Saugstad, J. A.; Saul, M. J.; Schiffelers, R. M.; Schneider, R.; Schoyen, T. H.; Scott, A.; Shahaj, E.; Sharma, S.; Shatnyeva, O.; Shekari, F.; Shelke, G. V.; Shetty, A. K.; Shiba, K.; Siljander, P. R.; Silva, A. M.; Skowronek, A.; Snyder, O. L., 2nd; Soares, R. P.; Sodar, B. W.; Soekmadji, C.; Sotillo, J.; Stahl, P. D.; Stoorvogel, W.; Stott, S. L.; Strasser, E. F.; Swift, S.; Tahara, H.; Tewari, M.; Timms, K.; Tiwari, S.; Tixeira, R.; Tkach, M.; Toh, W. S.; Tomasini, R.; Torrecilhas, A. C.; Tosar, J. P.; Toxavidis, V.; Urbanelli, L.; Vader, P.; van Balkom, B. W.; van der Grein, S. G.; Van Deun, J.; van Herwijnen, M. J.; Van Keuren-Jensen, K.; van Niel, G.; van Royen, M. E.; van Wijnen, A. J.; Vasconcelos, M. H.; Vechetti, I. J., Jr.; Veit, T. D.;


Page 17 of 22

389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437


17. 18. 19.

20. 21. 22. 23. 24. 25. 26. 27. 28. 29.

30.

Vella, L. J.; Velot, E.; Verweij, F. J.; Vestad, B.; Vinas, J. L.; Visnovitz, T.; Vukman, K. V.; Wahlgren, J.; Watson, D. C.; Wauben, M. H.; Weaver, A.; Webber, J. P.; Weber, V.; Wehman, A. M.; Weiss, D. J.; Welsh, J. A.; Wendt, S.; Wheelock, A. M.; Wiener, Z.; Witte, L.; Wolfram, J.; Xagorari, A.; Xander, P.; Xu, J.; Yan, X.; Yanez-Mo, M.; Yin, H.; Yuana, Y.; Zappulli, V.; Zarubova, J.; Zekas, V.; Zhang, J. Y.; Zhao, Z.; Zheng, L.; Zheutlin, A. R.; Zickler, A. M.; Zimmermann, P.; Zivkovic, A. M.; Zocco, D.; Zuba-Surma, E. K., Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018, 7 (1), 1535750. Vashisht, M.; Rani, P.; Onteru, S. K.; Singh, D., Curcumin Encapsulated in Milk Exosomes Resists Human Digestion and Possesses Enhanced Intestinal Permeability in Vitro. Appl Biochem Biotechnol 2017, 183 (3), 993-1007. Wang, B.; Zhuang, X.; Deng, Z. B.; Jiang, H.; Mu, J.; Wang, Q.; Xiang, X.; Guo, H.; Zhang, L.; Dryden, G.; Yan, J.; Miller, D.; Zhang, H. G., Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther 2014, 22 (3), 522-34. Ju, S.; Mu, J.; Dokland, T.; Zhuang, X.; Wang, Q.; Jiang, H.; Xiang, X.; Deng, Z. B.; Wang, B.; Zhang, L.; Roth, M.; Welti, R.; Mobley, J.; Jun, Y.; Miller, D.; Zhang, H. G., Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol Ther 2013, 21 (7), 1345-57. Wolf, T.; Baier, S. R.; Zempleni, J., The Intestinal Transport of Bovine Milk Exosomes Is Mediated by Endocytosis in Human Colon Carcinoma Caco-2 Cells and Rat Small Intestinal IEC-6 Cells. J Nutr 2015, 145 (10), 2201-6. Mu, J.; Zhuang, X.; Wang, Q.; Jiang, H.; Deng, Z. B.; Wang, B.; Zhang, L.; Kakar, S.; Jun, Y.; Miller, D.; Zhang, H. G., Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. Mol Nutr Food Res 2014, 58 (7), 1561-73. Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M. J., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29 (4), 341-5. Somiya, M.; Yoshioka, Y.; Ochiya, T., Biocompatibility of highly purified bovine milk-derived extracellular vesicles. J Extracell Vesicles 2018, 7 (1), 1440132. Aqil, F.; Kausar, H.; Agrawal, A. K.; Jeyabalan, J.; Kyakulaga, A. H.; Munagala, R.; Gupta, R., Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp Mol Pathol 2016, 101 (1), 12-21. Agrawal, A. K.; Aqil, F.; Jeyabalan, J.; Spencer, W. A.; Beck, J.; Gachuki, B. W.; Alhakeem, S. S.; Oben, K.; Munagala, R.; Bondada, S.; Gupta, R. C., Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine 2017, 13 (5), 1627-36. Aqil, F.; Jeyabalan, J.; Agrawal, A. K.; Kyakulaga, A. H.; Munagala, R.; Parker, L.; Gupta, R. C., Exosomal delivery of berry anthocyanidins for the management of ovarian cancer. Food Funct 2017, 8 (11), 4100-7. Zhao, Y.; Haney, M. J.; Gupta, R.; Bohnsack, J. P.; He, Z.; Kabanov, A. V.; Batrakova, E. V., GDNFtransfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse model. PloS one 2014, 9 (9), e106867. Kosaka, N.; Iguchi, H.; Yoshioka, Y.; Takeshita, F.; Matsuki, Y.; Ochiya, T., Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010, 285 (23), 17442-52. Zeelenberg, I. S.; Ostrowski, M.; Krumeich, S.; Bobrie, A.; Jancic, C.; Boissonnas, A.; Delcayre, A.; Le Pecq, J. B.; Combadiere, B.; Amigorena, S.; Thery, C., Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 2008, 68 (4), 1228-35. Piffoux, M.; Silva, A. K. A.; Wilhelm, C.; Gazeau, F.; Tareste, D., Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems. Acs Nano 2018, 12 (7), 6830-42.

438 17 ACS Paragon Plus Environment


Page 18 of 22

439

Table 1: Comparison of the key characteristics of biological nanoparticles (EVs) and artificial

440

nanoparticles (liposomes)

Stability Crossing barriers Immune tolerance Sources of material

Safety Methodology Loading capacity

Biological nanoparticles (EVs) Very stable by nature, resistant to digestion Able to cross complex barriers (e.g. blood-brain barrier) Dependent on source, but generally high tolerance Biological fluids from humans, animals or plants Food (milk, plants, fruits) In vitro production by cell lines Dependent on source Risks due to unknown biological functions High variability, no standardization Limited due to size

Artificial nanoparticles (liposomes) Engineered to be stable, dependent on materials Not able to cross complex barriers Needs engineering to achieve (e.g. polyethylene glycol Artificial materials Food-grade materials

Risks are well known due to many studies addressing safety Established methods of nanotechnology Variable, limit depends on application

441 442


Page 19 of 22


443

Figure Captions

444

Figure 1. Treemap chart of the records found in the Web of Science search “extracellular

445

vesicl* OR exosome* OR microvesicle*” of the year 2017, categorized in Web of Science

446

categories, top 15 categories are displayed.

447

Figure2. A Schematic of the biogenesis of two types of EVs, microvesicles and exosomes, by a

448

cell. MVB – multivesicular body. B Cryo-electron microscopy images of EVs labelled with gold

449

nanoparticles, reprinted from 12.



Page 20 of 22

Figure 1


Page 21 of 22


Figure 2 A

B



Page 22 of 22

Table of Contents Graphic


Extracellular Vesicles as Vehicles for the Delivery ... - ACS Publications

Recommend Documents